Cluny Lefevre, DO
Family Medicine · New York, NYNPI 1477505147
Payments from drug & device makers
Across 542 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- AbbVie$950
- Gilead$820
- plus $3K from 24 others
What the payments were for
- Food & beverage$10,14399%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 87 | $1,606 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 87 | $1,251 |
| AstraZeneca | 64 | $1,178 |
| Boehringer Ingelheim | 48 | $1,136 |
| AbbVie(2 entities) | 57 | $950 |
| Gilead | 36 | $820 |
| Amgen(2 entities) | 30 | $577 |
| Lilly USA, LLC | 29 | $568 |
| Viiv Healthcare Company | 16 | $460 |
| Novo Nordisk | 17 | $329 |
| Exact Sciences | 15 | $270 |
| Pfizer | 11 | $194 |
| Amarin Pharma, Inc. | 9 | $178 |
| Astellas Pharma US Inc | 2 | $108 |
| Lundbeck LLC | 5 | $80 |
| Ardelyx, Inc. | 4 | $67 |
| Bayer | 4 | $64 |
| Ironwood Pharmaceuticals, Inc | 3 | $60 |
| Merck | 4 | $59 |
| Phathom Pharmaceuticals, Inc. | 2 | $52 |
| Otsuka America Pharmaceutical, Inc. | 1 | $50 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| Intra-sana Laboratories | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $13 |
| Renalytix AI, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,243 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $100,940 |
| RybelsusSemaglutide | 45 | $53,181 |
| JardianceEmpagliflozin | 42 | $52,370 |
| JanuviaSitagliptin Phosphate | 30 | $40,377 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $37,399 |
| FarxigaDapagliflozin Propanediol | 38 | $36,748 |
| JanumetSitagliptin Phos/Metformin Hcl | 45 | $34,336 |
| LinzessLinaclotide | 59 | $30,496 |
| EliquisApixaban | 33 | $26,511 |
| TrulicityDulaglutide | 27 | $25,170 |
| JentaduetoLinagliptin/Metformin Hcl | 25 | $12,284 |
| VascepaIcosapent Ethyl | 22 | $11,506 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 225 | $7,506 |
| NamzaricMemantine Hcl/Donepezil Hcl | 11 | $7,173 |
| TrulancePlecanatide | 12 | $6,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $329 | $154,121126 claims |
| MerckJanuvia, Janumet | $59 | $74,71375 claims |
| Boehringer IngelheimJardiance, Jentadueto | $1,136 | $64,65467 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,606 | $43,47464 claims |
| AbbVieLinzess, Namzaric, Synthroid | $950 | $39,14890 claims |
| AstraZenecaFarxiga | $1,178 | $36,74838 claims |
| PfizerEliquis | $194 | $26,51133 claims |
| Lilly USA, LLCTrulicity | $568 | $25,17027 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $1,251 | $6,58012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in New York
- Matthew PabisNew York$222K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
- Jason KindtNew York$122K
- Punyadech PhotangthamNew York$107K
- Mahyar EidgahNew York$76K
- Anthony LyonNew York$65K
- Daniel BowersNew York$44K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.